Bi-specific Antibodies in Treating Multiple Myeloma

Exploring the use of three bi-specific antibodies for relapsed/refractory multiple myeloma, detailing their adverse effects, supportive care, and impact on shifting treatment options. Focus on BCMA-directed bispecific antibodies' effectiveness, response patterns, manageable side effects, and promising results in patients with prior BCMA exposures.